ES2604586T3 - Uso terapéutico de la neurotoxina botulínica de Tipo A en el tratamiento del dolor asociado a la neuropatía diabética - Google Patents

Uso terapéutico de la neurotoxina botulínica de Tipo A en el tratamiento del dolor asociado a la neuropatía diabética Download PDF

Info

Publication number
ES2604586T3
ES2604586T3 ES09734803.1T ES09734803T ES2604586T3 ES 2604586 T3 ES2604586 T3 ES 2604586T3 ES 09734803 T ES09734803 T ES 09734803T ES 2604586 T3 ES2604586 T3 ES 2604586T3
Authority
ES
Spain
Prior art keywords
botulinum neurotoxin
treatment
pain associated
diabetic neuropathy
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09734803.1T
Other languages
English (en)
Inventor
Christine Favre
Michel Auguet
Pierre-Etienne Chabrier De Lassauniere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Application granted granted Critical
Publication of ES2604586T3 publication Critical patent/ES2604586T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una neurotoxina botulínica de tipo A para uso en el tratamiento del dolor asociado a la neuropatía diabética, donde dicha neurotoxina botulínica se prepara para administración local limitada a un sitio del cuerpo en un sitio que está distante del sitio dolorido, donde la administración local no es en el sistema central nervioso (SNC), y donde se logra un efecto analgésico en el lado ipsilateral y en el lado contra-lateral.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES09734803.1T 2008-04-25 2009-04-27 Uso terapéutico de la neurotoxina botulínica de Tipo A en el tratamiento del dolor asociado a la neuropatía diabética Active ES2604586T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0802321 2008-04-25
FR0802321A FR2930447B1 (fr) 2008-04-25 2008-04-25 Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
PCT/IB2009/005750 WO2009130600A2 (en) 2008-04-25 2009-04-27 Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy

Publications (1)

Publication Number Publication Date
ES2604586T3 true ES2604586T3 (es) 2017-03-07

Family

ID=39968086

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09734803.1T Active ES2604586T3 (es) 2008-04-25 2009-04-27 Uso terapéutico de la neurotoxina botulínica de Tipo A en el tratamiento del dolor asociado a la neuropatía diabética

Country Status (6)

Country Link
US (2) US8784841B2 (es)
EP (2) EP2280719B1 (es)
CA (1) CA2720994C (es)
ES (1) ES2604586T3 (es)
FR (1) FR2930447B1 (es)
WO (1) WO2009130600A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
PT2085093E (pt) * 2006-10-27 2015-06-26 Chemo Sero Therapeut Res Inst Preparação que contém uma toxina botulínica tipo a altamente purificada derivada de um agente patogénico do botulismo infantil
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
UA116985C2 (uk) 2012-05-30 2018-06-11 Президент Енд Феллоуз Оф Гарвард Колледж Рекомбінантний ботулінічний нейротоксин
DK3274364T3 (da) 2015-03-26 2021-10-18 Harvard College Modificeret botulinumneurotoksin
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
GB201907016D0 (en) * 2019-05-17 2019-07-03 Ipsen Biopharm Ltd Screening method to determine suitability for participation in a clinical trial
CN115040641A (zh) * 2022-06-29 2022-09-13 无锡市太湖医院 神经外科术前干预药物组合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
EP0737074B1 (en) 1993-12-28 2001-08-01 Allergan Sales, Inc. Botulinum toxins for treating hyperhydrosis
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US6136551A (en) 1995-04-24 2000-10-24 Allergan, Inc. Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
AU4904101A (en) 1999-12-08 2001-07-09 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
CN1258379C (zh) 2000-02-08 2006-06-07 阿勒根公司 肉毒杆菌毒素药物组合物
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
KR20030018827A (ko) 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
WO2004075832A2 (en) 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
WO2004084839A2 (en) 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
GB2417419A (en) 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP1622009A1 (en) * 2004-07-27 2006-02-01 Texas Instruments Incorporated JSM architecture and systems
GB2419526A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
GB2416692A (en) * 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
WO2006042249A2 (en) 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
AR053098A1 (es) 2004-11-04 2007-04-25 Toray Industries Analgesico derivado de morfinano
US20090232849A1 (en) * 2005-03-03 2009-09-17 Universite Catholique De Louvain Methods and compositions for the treatment of cancer
US20090214466A1 (en) * 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
FR2888116A1 (fr) * 2005-07-08 2007-01-12 Sod Conseils Rech Applic Derives de thiazoles pour traiter les dyskinesies
KR100726441B1 (ko) * 2005-11-22 2007-06-11 삼성전자주식회사 현상장치 및 이를 이용한 화상형성장치
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
EP2510098B1 (en) * 2009-12-09 2015-02-11 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US8895537B2 (en) * 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases

Also Published As

Publication number Publication date
WO2009130600A8 (en) 2010-08-12
US20140154781A1 (en) 2014-06-05
WO2009130600A3 (en) 2009-12-17
US8784841B2 (en) 2014-07-22
CA2720994A1 (en) 2009-10-29
CA2720994C (en) 2016-10-04
US9259458B2 (en) 2016-02-16
US20110038893A1 (en) 2011-02-17
EP3173090A1 (en) 2017-05-31
FR2930447A1 (fr) 2009-10-30
EP2280719B1 (en) 2016-09-07
WO2009130600A2 (en) 2009-10-29
FR2930447B1 (fr) 2010-07-30
EP2280719A2 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
ES2604586T3 (es) Uso terapéutico de la neurotoxina botulínica de Tipo A en el tratamiento del dolor asociado a la neuropatía diabética
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
ES2496892T3 (es) Formulaciones para el tratamiento de trastornos del tracto respiratorio superior
ES2532850T3 (es) Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso
CR20130201A (es) Dispositivos para suministrar un medicamento y método para aliviar el dolor
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
CO6771406A2 (es) Una composición combinada
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
MX359672B (es) Metodo para manejo de dolor cronico y tratamiento usando hcg.
DOP2019000072A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
AR065085A1 (es) Metodo para tratamiento prolongado del acne vulgaris
TW201642906A (en) Fixed dose combination for pain relief without edema
ES2561813T3 (es) Aplicación tópica de nimesulida y tiocolchicósido
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico